About 1 in 7 women develops postpartum depression (PPD) after giving birth. In a press release this summer announcing the approval of Zurzuvae, the first oral medication designed to treat PPD in women, Dr. Tiffany Farchione, director of the psychiatry division in the Food and Drug Administration’s Center for Drug Evaluation and Research, described it as a “potentially life-threatening condition in which women experience sadness, guilt, worthlessness — even, in severe cases, thoughts of harming themselves or their child.”
